

Pulmonary Embolism: Diagnostic Approach, Clinical Findings, and the Alarming Rise in Incidence – A Critical Review

Azam Iqbal¹, Khalid Usman², Muhammad Talha³, Reena Sebastina Irudayaraj⁴

¹⁻³Medical Resident at Sharurah General Hospital, Sharurah KSA, ⁴Staff Nurse at Sharurah General Hospital, Sharurah KSA

Correspondence to: Dr. Azam Iqbal, Phone: +966-502516142, Email: abdulrashid@moh.gov.sa

ABSTRACT

Background: Pulmonary embolism (PE) is a potentially life-threatening condition resulting from the obstruction of pulmonary arteries, most commonly by thrombi originating from the deep veins of the lower limbs. In recent years, a notable rise in PE incidence has been observed globally, attributed to both improved detection and an increase in predisposing risk factors.

Objective: To provide a comprehensive overview of the evolving epidemiology, diagnostic approach, clinical features, therapeutic options, and long-term outcomes of PE, with emphasis on the critical rise in incidence and implications for clinical practice.

Methods: A narrative review was conducted using recent peer-reviewed literature and guideline-based recommendations. Studies were selected from indexed databases focusing on diagnostic algorithms, imaging modalities, treatment outcomes, and epidemiological trends related to acute PE.

Results: PE incidence is increasing globally, driven by aging populations, cancer survivorship, and postoperative complications. Clinical presentation varies widely, often mimicking other cardiopulmonary conditions, making early diagnosis challenging. Risk stratification tools such as the Wells score, revised Geneva score, and Pulmonary Embolism Severity Index (PESI) are critical in guiding the use of D-dimer testing and imaging. Computed tomography pulmonary angiography (CTPA) remains the diagnostic gold standard. Treatment strategies are guided by risk categories—ranging from anticoagulation alone in low-risk cases to thrombolysis or surgical embolectomy in high-risk cases. Long-term complications such as chronic thromboembolic pulmonary hypertension (CTEPH) and post-PE syndrome significantly impact quality of life, underscoring the importance of follow-up and rehabilitation.

Conclusion: The increasing incidence and variable presentation of PE demand heightened clinical vigilance. Early risk-adapted diagnosis and intervention are pivotal in reducing mortality and morbidity. Long-term monitoring and individualized therapy are essential for improving patient outcomes. Future strategies should emphasize prevention, early detection, and research into novel diagnostic and therapeutic tools.

Keywords:

Pulmonary embolism, Venous thromboembolism, Anticoagulation, Post-PE syndrome

INTRODUCTION

Pulmonary embolism (PE) is a critical and potentially fatal cardiovascular condition characterized by the obstruction of pulmonary arteries, most commonly due to thrombi originating from the deep veins of the lower extremities. It constitutes a major clinical emergency, ranking as the third most common cause of cardiovascular death after myocardial infarction and stroke¹. Despite increased awareness and diagnostic advances, PE continues to be underdiagnosed due to its diverse and often non-specific clinical presentations².

In recent years, the global incidence of PE has shown a noticeable upward trend. While part of this rise can be attributed to the increased utilization of advanced imaging techniques such as computed tomography pulmonary angiography (CTPA), other contributors include aging populations, sedentary lifestyles, obesity, malignancy, and notably, the hypercoagulable state associated with COVID-19 infections^{3,4}. Studies have demonstrated that patients hospitalized with COVID-19 are at a significantly increased risk of venous thromboembolism, including

PE, due to endothelial dysfunction, systemic inflammation, and prolonged immobilization⁵.

This trend burdens healthcare systems, necessitating better strategies for early detection and risk-adapted management. A comprehensive understanding of clinical predictors, diagnostic modalities, and risk assessment tools is imperative to reduce diagnostic delays and improve outcomes. Moreover, the recent epidemiological changes call for a re-evaluation of current guidelines and prevention protocols in both inpatient and outpatient settings.

This article critically reviews the current diagnostic approach to PE, outlines key clinical features, and examines the alarming rise in incidence, especially in the post-COVID era. The objective is to provide a consolidated update for clinicians and researchers to enhance early detection and management of this life-threatening condition.

Conflict of interest: The authors declared no conflict of interest exists.
Citation: Iqbal A, Usman K, Talha M, Irudayaraj RS. Pulmonary Embolism: Diagnostic Approach, Clinical Findings, and the Alarming Rise in Incidence – A Critical Review. J Fatima Jinnah Med Univ. 2024;18(1):48-56.
DOI: 10.37018/JFJMU/AI/2990

Epidemiological Trends and Rising Incidence of Pulmonary Embolism

Pulmonary embolism (PE) has long been recognized as a significant cause of cardiovascular morbidity and mortality, but recent decades have witnessed a striking rise in its reported incidence. In the United States alone, PE affects an estimated 60 to 70 per 100,000 individuals annually, with some studies reporting even higher rates in specific subgroups⁶. While improved diagnostic sensitivity plays a partial role, the increase cannot be solely attributed to enhanced detection; there is growing concern that the actual burden of disease is rising due to evolving risk factors and societal trends⁷.

Improved Detection or True Increase

The widespread availability and utilization of computed tomography pulmonary angiography (CTPA) since the early 2000s have dramatically improved the detection of PE, especially smaller, sub-segmental emboli that were previously undiagnosed⁸. Studies have shown that the incidence of PE more than doubled between 1998 and 2006, coinciding with the introduction of multi-detector CT scanners⁹. However, this diagnostic shift also introduced concerns of over-diagnosis - identifying clinically insignificant emboli that may not require treatment¹⁰.

Nevertheless, hospitalizations and outpatient diagnoses for PE have also increased, accompanied by growing rates of anticoagulant use and healthcare resource utilization, suggesting that a true epidemiological shift is underway¹¹.

Contributing Factors to Rising Incidence

Several demographic, behavioral, and clinical variables have contributed to the rising incidence of PE:

Aging Population: Age is one of the most important risk factors for PE, with incidence doubling with each subsequent decade after 50 years¹².

Obesity and Sedentary Lifestyle: The global obesity epidemic and increasing sedentary behavior have led to a surge in venous thromboembolism (VTE) events, including PE¹³. Obesity is an independent risk factor, possibly due to increased inflammatory markers, endothelial dysfunction, and impaired venous return¹⁴.

Cancer: With improved cancer detection and survival, more patients are living longer with malignancy, which is a well-established prothrombotic state. Both solid and hematologic malignancies significantly elevate PE risk, especially in those receiving chemotherapy or undergoing surgery¹⁵.

Surgical and Hospital Admissions: Despite widespread use of prophylactic anticoagulation, postoperative PE remains a notable complication, particularly following orthopedic, oncologic, and abdominal procedures¹⁶.

Hormonal Therapies and Pregnancy: Estrogen-based therapies and pregnancy/postpartum states are well-known risk factors, and increased use of hormone replacement therapy and assisted reproductive technologies may be contributing to incidence trends¹⁷.

COVID-19 Pandemic: A paradigm-shifting event in recent PE epidemiology has been the COVID-19 pandemic. SARS-CoV-2 infection induces endothelial injury, cytokine storm, and a hypercoagulable state, leading to increased incidence of PE, especially in hospitalized and ICU patients¹⁸. Autopsy studies and clinical reports have consistently documented high rates of thrombotic complications among COVID-19 patients, prompting new anticoagulation protocols¹⁹.

Global Variations in Incidence

PE incidence varies significantly across regions, influenced by diagnostic resources, population demographics, and reporting systems. Developed countries with greater access to imaging report higher rates, while low- and middle-income countries often face under-diagnosis due to lack of resources and awareness²⁰. Moreover, regional differences in risk factors like obesity, smoking, and healthcare access further contribute to incidence variability.

Mortality and Recurrent PE

While PE-related mortality has declined slightly over time due to earlier detection and treatment, it remains alarmingly high, especially in untreated or misdiagnosed cases. Massive PE, characterized by hemodynamic instability, carries a mortality rate exceeding 25%²¹. Recurrent PE is also common in patients without appropriate secondary prophylaxis, further underlining the importance of effective initial management and follow-up care²².

Clinical Presentation and Risk Factors

The clinical presentation of pulmonary embolism (PE) is notoriously variable, ranging from asymptomatic cases to sudden cardiovascular collapse and death. This variability contributes to the diagnostic challenge and underscores the importance of clinical suspicion, especially in high-risk patients²³. The classic triad of dyspnea, pleuritic chest pain, and hemoptysis is rarely seen in combination, and most patients present with nonspecific symptoms that mimic other cardiopulmonary conditions²⁴.

Common Clinical Manifestations

The most frequently reported symptoms and signs of PE include²⁵:

- Dyspnea (73%) – Often of sudden onset and unexplained
- Pleuritic chest pain (44%)
- Tachypnea (54%) – The most common physical sign
- Tachycardia (24–30%)
- Cough (34%)

- Hemoptysis (rare, ~13%)
- Syncope – Often associated with massive PE and right ventricular dysfunction
- Signs of deep vein thrombosis (DVT) – Leg swelling or tenderness in 15–25% of cases

Despite these common features, atypical presentations are not uncommon, particularly in the elderly, pregnant patients, or those with comorbidities such as chronic obstructive pulmonary disease (COPD), heart failure, or malignancy²⁶. In such populations, PE may masquerade as pneumonia, exacerbation of asthma or COPD, or acute coronary syndrome.

Severity-Based Classification

PE is stratified into three clinical categories based on hemodynamic stability and right ventricular function, which also guide management strategies²⁷:

Massive PE: Characterized by sustained hypotension (SBP <90 mmHg), shock, or cardiac arrest. Mortality exceeds 25%.

Submassive PE: Hemodynamically stable but with right ventricular dysfunction or elevated cardiac biomarkers.

Low-risk PE: No hemodynamic compromise or right ventricular involvement.

This classification helps clinicians decide the urgency and intensity of interventions, including systemic thrombolysis or catheter-based therapy²⁸.

Risk Factors

Pulmonary embolism results from a combination of venous stasis, endothelial injury, and hypercoagulability—collectively known as Virchow's triad²⁹.

Numerous acquired and inherited risk factors contribute to this pathogenesis:

1. Acquired Risk Factors:

Recent surgery or trauma: Especially orthopedic or abdominal procedures increase risk significantly³⁰.

Prolonged immobilization: Includes hospitalization, long-haul travel, or sedentary lifestyle³¹.

Cancer: Particularly adenocarcinomas (e.g., pancreas, lung, gastrointestinal tract)³².

Pregnancy and postpartum period: Risk is highest during the first six weeks after delivery³³.

Estrogen therapy: Oral contraceptives and hormone replacement therapy increase thrombotic risk³⁴.

COVID-19 infection: A powerful prothrombotic stimulus due to cytokine storm, endothelial dysfunction, and immobilization³⁵.

2. Inherited Thrombophilias:

- Factor V Leiden mutation
- Prothrombin G20210A mutation
- Protein C, Protein S, or antithrombin III deficiency

- Hyperhomocysteinemia

These conditions predispose individuals to both unprovoked and recurrent thromboembolic events, particularly in younger patients without obvious risk factors³⁶.

3. Recurrent and Idiopathic PE:

Approximately 20–30% of patients with PE have no identifiable provoking factor. These unprovoked or idiopathic PEs warrant further evaluation for occult malignancy or thrombophilia and require long-term anticoagulation due to high recurrence risk³⁷.

4. Special Populations

Elderly: Diagnosis is frequently delayed or missed in older adults, where dyspnea or hypoxia is often attributed to underlying cardiac or pulmonary disease. Moreover, age itself is a strong independent risk factor for PE³⁸.

Pregnant Women: PE is a leading cause of maternal mortality worldwide. The diagnostic dilemma is heightened by overlapping symptoms with normal pregnancy, and the use of imaging is often limited by fetal safety concerns³⁹.

Hospitalized and ICU Patients: High rates of VTE are seen in critically ill or post-operative patients, necessitating routine prophylaxis protocols. Despite this, underutilization of prophylactic anticoagulation remains a global issue⁴⁰.

Diagnostic Approach to Pulmonary Embolism

Given the often nonspecific clinical manifestations of pulmonary embolism (PE), timely and accurate diagnosis remains one of the most challenging aspects of its management. The cornerstone of an effective diagnostic strategy lies in the integration of clinical prediction rules, biochemical markers, and imaging modalities, tailored to the patient's risk profile⁴¹. Inappropriate use of diagnostic tests may result in overdiagnosis, overtreatment, or missed diagnoses, all of which carry significant consequences⁴².

1. Clinical Prediction Rules

Validated clinical probability scoring systems serve as essential tools to estimate the pretest probability of PE and guide further diagnostic steps:

a. Wells Score

The Wells criteria are the most widely used and stratify patients into low, intermediate, or high probability groups based on factors such as signs of DVT, previous PE/DVT, heart rate, immobilization, and clinical suspicion⁴³. Simplified Wells Score Interpretation:

- ≤4 points: PE unlikely
- >4 points: PE likely

Patients in the “PE unlikely” category with a negative D-dimer can often avoid imaging, significantly reducing unnecessary radiation and cost⁴⁴.

b. Revised Geneva Score

An alternative, entirely objective tool, the revised Geneva score, uses age, heart rate, recent surgery, and hemoptysis among others. It is especially useful in settings where subjective clinical judgment may vary⁴⁵.

2. D-dimer Assay

D-dimer, a fibrin degradation product, is a sensitive marker for ongoing thrombosis. Elevated levels indicate thrombus formation and degradation, though the test lacks specificity⁴⁶. It is most valuable in low or intermediate-risk patients, where a normal D-dimer level (<500 ng/mL) can effectively exclude PE without imaging⁴⁷.

In patients over 50 years, an age-adjusted cutoff improves specificity without compromising sensitivity:

Adjusted D-dimer threshold = Age (in years) × 10 ng/mL for patients >50 years⁴⁸.

However, D-dimer levels can also be elevated in various other conditions (e.g., infection, trauma, cancer, pregnancy), limiting its standalone utility⁴⁹.

3. Imaging Modalities

Imaging is the definitive step in confirming or excluding PE in moderate- to high-risk patients or those with positive D-dimer tests.

a. Computed Tomography Pulmonary Angiography (CTPA)

CTPA is the gold standard for PE diagnosis due to its high sensitivity and specificity, rapid availability, and ability to visualize alternative diagnoses⁵⁰. It can detect emboli down to sub-segmental arteries and assess right ventricular strain, which has prognostic implications⁵¹.

Limitations:

- Requires contrast — contraindicated in renal impairment or contrast allergy
- Radiation exposure — relevant for pregnant or young patients

b. Ventilation-Perfusion (V/Q) Scan

A V/Q scan evaluates mismatch between ventilation and perfusion in lung segments. It is especially useful in pregnant women, young individuals, and those with renal dysfunction⁵².

- Normal scan: Excludes PE
- High-probability scan: Strongly supports PE diagnosis in appropriate clinical context

V/Q scans have lower sensitivity than CTPA in patients with abnormal chest radiographs or underlying lung disease⁵³.

c. Compression Ultrasonography

Given that most PEs originate from DVTs, bilateral lower limb venous ultrasonography can aid diagnosis, especially when imaging is delayed or contraindicated.

A positive DVT in a symptomatic patient can justify empirical anticoagulation⁵⁴.

4. Role of Echocardiography and Biomarkers

a. Transthoracic Echocardiography (TTE)

While not diagnostic for PE, TTE is crucial in hemodynamically unstable patients. It can reveal right ventricular dilation, hypokinesis, and elevated pulmonary artery pressures — signs of massive or submassive PE⁵⁵.

b. Cardiac Biomarkers

Troponin and brain natriuretic peptide (BNP) levels may be elevated in PE with right heart strain, serving as prognostic markers⁵⁶.

Elevated biomarkers, in conjunction with imaging, help risk-stratify and identify candidates for thrombolysis⁵⁷.

5. Diagnostic Algorithm (Overview)

Assess clinical probability using Wells or Geneva score.

- If PE is unlikely → D-dimer:
- If negative → rule out PE
- If positive → proceed to CTPA
- If PE is likely or patient is high risk → CTPA directly
- If CTPA contraindicated → V/Q scan or leg ultrasound
- In unstable patients → Echocardiography for RV strain; start empiric treatment if needed

This stepwise approach ensures efficient diagnosis while minimizing unnecessary testing and exposure⁵⁸.

Management of Pulmonary Embolism

The management of pulmonary embolism is a nuanced process that varies based on clinical severity, hemodynamic stability, and comorbidities. The primary goals are to prevent clot progression, reduce cardiopulmonary strain, and prevent recurrence or death. Treatment decisions range from anticoagulation to thrombolysis, interventional procedures, and in some cases, supportive care or surgical embolectomy.

1. Risk Stratification and Initial Management

Effective PE management begins with risk stratification, which categorizes patients into:

- High-risk (massive PE): Hemodynamic instability (SBP <90 mmHg or shock)
- Intermediate-risk (submassive PE): Right ventricular (RV) dysfunction or elevated biomarkers without shock
- Low-risk PE: Hemodynamically stable, no RV dysfunction or elevated troponin⁵⁹

Initial supportive measures include:

- Oxygen therapy
- Hemodynamic support (IV fluids, vasopressors if necessary)

- Monitoring in ICU or telemetry for high/intermediate-risk cases⁶⁰

2. Anticoagulation: Mainstay of Therapy

Anticoagulation prevents further thrombus propagation and allows endogenous fibrinolysis to occur. It should be initiated as soon as PE is suspected, provided there's no major bleeding risk⁶¹.

a. Initial Anticoagulants

- Low Molecular Weight Heparin (LMWH): Preferred in cancer and pregnancy
- Unfractionated Heparin (UFH): Preferred if rapid reversal is anticipated
- Fondaparinux: Synthetic factor Xa inhibitor with predictable kinetics⁶²

b. Direct Oral Anticoagulants (DOACs)

Rivaroxaban, apixaban, dabigatran, and edoxaban are increasingly favored due to oral administration, predictable pharmacokinetics, and no need for routine INR monitoring⁶³. Studies show comparable efficacy and improved safety profiles versus warfarin⁶⁴.

Rivaroxaban: 15 mg BID for 21 days → 20 mg OD

Apixaban: 10 mg BID for 7 days → 5 mg BID

Dabigatran/Edoxaban: Require 5–10 days of parenteral anticoagulation first⁶⁵

c. Warfarin

Used less frequently today; requires INR monitoring and bridging with heparin for at least 5 days⁶⁶.

3. Thrombolytic Therapy

Systemic thrombolysis is reserved for high-risk PE with shock or persistent hypotension, as it rapidly reduces clot burden and RV afterload⁶⁷.

- Agents: Alteplase 100 mg over 2 hours (or adjusted for body weight)
- Benefits: Reduced mortality and hemodynamic deterioration
- Risks: Major bleeding, especially intracranial hemorrhage (~2%)⁶⁸

Intermediate-risk PE: Controversial. Routine use of thrombolysis is not recommended, but may be considered in select cases with RV dysfunction and worsening symptoms⁶⁹.

4. Catheter-Directed Therapies (CDT)

In patients with contraindications to systemic thrombolysis or refractory shock, catheter-based thrombolysis or thrombectomy may be performed:

- Ultrasound-assisted thrombolysis (USAT)
- Mechanical thrombectomy
- Local delivery of lower-dose thrombolytics

These methods reduce bleeding risk while preserving efficacy, especially in experienced centers⁷⁰.

5. Surgical Embolectomy

Reserved for:

- Massive PE with contraindication to thrombolysis

- Failure of thrombolysis or CDT
- Large proximal thrombi (e.g., saddle PE) causing obstruction

Though invasive, surgical embolectomy has improved outcomes when performed early and in high-volume centers⁷¹.

6. Inferior Vena Cava (IVC) Filters

IVC filters do not treat PE but may prevent recurrent embolism in:

- Patients with absolute contraindications to anticoagulation
- Recurrent PE despite anticoagulation

Their use should be temporary and retrievable filters are preferred. Long-term placement is associated with increased DVT risk⁷².

Duration of Anticoagulation

Clinical Scenario	Duration
PE provoked by surgery	3 months
PE provoked by transient risk factor	3–6 months
Unprovoked PE	≥3 months, possibly lifelong
PE in cancer	At least 6 months, ongoing
Recurrent PE or thrombophilia	Long-term/lifelong

Long-term decisions should balance bleeding risk vs recurrence risk, using tools like HAS-BLED or VTE-BLED scores⁷³.

Management in Special Populations

a. Pregnancy

LMWH is the treatment of choice; DOACs and warfarin are contraindicated. Diagnosis often relies on V/Q scan over CTPA to reduce fetal radiation⁷⁴.

b. Cancer-associated PE

LMWH was previously preferred, but newer studies favor DOACs (e.g., apixaban, edoxaban) due to ease of use and non-inferior efficacy⁷⁵.

c. Elderly and Renal Impairment

Dose adjustments and bleeding risk assessments are crucial. DOACs may accumulate in renal impairment; monitor renal function regularly⁷⁶.

Prognosis and Long-Term Outcomes

Despite therapeutic advances, pulmonary embolism (PE) remains a potentially fatal condition. The prognosis depends largely on early recognition, appropriate risk stratification, and timely intervention. Even after acute management, long-term complications such as chronic thromboembolic pulmonary hypertension (CTEPH) and recurrent venous thromboembolism (VTE) significantly affect morbidity.

1. Short-Term Prognosis

a. Mortality

- Acute PE has an overall 30-day mortality of 5–15%, with higher rates in high-risk (massive) PE⁷⁷.

- In hemodynamically unstable PE, mortality may exceed 30–50% without thrombolytic or surgical intervention⁷⁸.

b. Prognostic Indicators

- RV dysfunction, elevated troponins, and BNP levels are associated with poor outcomes⁷⁹.
- Risk stratification tools like PESI (Pulmonary Embolism Severity Index) and sPESI help predict short-term mortality and guide treatment intensity⁸⁰.

2. Recurrence of VTE

- Approximately 25–30% of patients experience recurrent VTE within 10 years⁸¹.
- Risk is highest in patients with unprovoked PE, thrombophilia, cancer, or non-adherence to anticoagulation.
- Prolonged or indefinite anticoagulation is considered in high-risk groups⁸².

3. Post-PE Syndrome

A subset of patients experience persistent dyspnea, exercise intolerance, and reduced quality of life, even without objective cardiopulmonary abnormalities. This condition is referred to as post-PE syndrome, affecting 30–50% of survivors⁸³.

Causes include deconditioning, mild residual pulmonary hypertension, and psychological sequel such as anxiety or PTSD.

4. Chronic Thromboembolic Pulmonary Hypertension (CTEPH)

CTEPH is a serious long-term complication characterized by persistent obstruction of pulmonary arteries, leading to pulmonary hypertension and right heart failure. It occurs in about 3–4% of patients after acute PE⁸⁴.

Suspected in patients with dyspnea >3 months post-PE despite anticoagulation and confirmed by:

- Ventilation-perfusion (V/Q) scan: Shows mismatched perfusion defects
- Right heart catheterization
- Pulmonary angiography or CT-PA for surgical planning

Pulmonary endarterectomy (PEA) is the treatment of choice in eligible patients, with >90% survival at 5 years in expert centers⁸⁶.

Medical therapy (e.g., riociguat) or balloon pulmonary angioplasty is considered in inoperable cases⁸⁷.

5. Quality of Life and Functional Recovery

Even after successful treatment, many patients experience:

- Fatigue
- Reduced exercise tolerance
- Emotional distress, especially fear of recurrence

Rehabilitation programs focusing on physical conditioning, psychological support, and education can significantly improve outcomes⁸⁸.

6. Follow-Up Recommendations

- 3-month review: Reassess for symptoms, RV function, anticoagulation adherence
- 6–12 months: Evaluate for post-PE syndrome or CTEPH if symptoms persist
- D-dimer testing and thrombophilia workup (if indicated) may help determine duration of anticoagulation⁸⁹

Conclusion

Pulmonary embolism (PE) remains a critical and increasingly prevalent cardiovascular emergency, posing significant diagnostic and therapeutic challenges. The rising global incidence, in part due to improved imaging, aging populations, and heightened awareness, necessitates a proactive clinical approach. Despite advances in risk stratification tools, non-invasive imaging, and anticoagulant therapies, PE continues to cause considerable morbidity and mortality, especially when diagnosis or treatment is delayed.

A thorough understanding of clinical presentation, risk factors, and pathophysiology is vital for timely identification. The use of validated diagnostic algorithms, biomarkers, and clinical probability scores can significantly improve diagnostic accuracy while reducing unnecessary imaging. Treatment must be tailored based on risk stratification, encompassing anticoagulation, thrombolysis, or interventional procedures, alongside consideration for comorbidities and bleeding risk.

Long-term follow-up is essential to detect and manage complications such as CTEPH, post-PE syndrome, and recurrent VTE. Additionally, patient education, lifestyle modification, and rehabilitation play critical roles in improving outcomes and quality of life.

Given the notable burden of disease, continuous efforts are needed to refine diagnostic strategies, personalize therapeutic interventions, and ensure comprehensive follow-up. Integrating emerging technologies, biomarker profiling, and real-world risk assessment tools could further enhance outcomes in the evolving landscape of PE care.

Limitations: This review presents a comprehensive synthesis of the diagnostic and therapeutic landscape of pulmonary embolism; however, several limitations should be acknowledged. First, as a narrative review, it is subject to selection bias in the inclusion of studies and may lack the systematic rigor of meta-analyses. The heterogeneity of data from different healthcare settings, populations, and diagnostic protocols limits the generalizability of findings. Additionally, rapidly evolving evidence, especially in the context of COVID-19-associated thrombosis, means that newer data may have emerged since the time of writing. The review also does not delve

deeply into pediatric PE, pregnancy-associated PE, or genetic thrombophilias, which represent unique subgroups with specific diagnostic and management considerations. Furthermore, while clinical prediction rules and imaging modalities are discussed, real-world adherence to these protocols and resource limitations in low-income settings are not addressed in depth. Finally, although long-term outcomes such as chronic thromboembolic pulmonary hypertension (CTEPH) and post-PE syndrome are highlighted, data on their incidence, predictors, and optimal management remain incomplete and warrant further prospective research.

REFERENCES

- Konstantinides SV, Meyer G, Becattini C, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). *Eur Heart J*. 2020;41(4):543–603.
- Raja AS, Greenberg JO, Qaseem A, et al. Evaluation of Patients With Suspected Acute Pulmonary Embolism: Best Practice Advice From the Clinical Guidelines Committee of the American College of Physicians. *Ann Intern Med*. 2015;163(9):701–711.
- Wiener RS, Schwartz LM, Woloshin S. Time trends in pulmonary embolism in the United States: Evidence of overdiagnosis. *Arch Intern Med*. 2011;171(9):831–837.
- Bikdeli B, Madhavan MV, Jimenez D, et al. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up. *J Am Coll Cardiol*. 2020;75(23):2950–2973.
- Klok FA, Kruip MJHA, van der Meer NJM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. *Thromb Res*. 2020;191:145–147.
- Beckman MG, Hooper WC, Critchley SE, Ortel TL. Venous thromboembolism: a public health concern. *Am J Prev Med*. 2010;38(4 Suppl):S495–501.
- Horlander KT, Mannino DM, Leeper KV. Pulmonary embolism mortality in the United States, 1979–1998: An analysis using multiple-cause mortality data. *Arch Intern Med*. 2003;163(14):1711–1717.
- Remy-Jardin M, Remy J, Wattrinne L, Giraud F. Central pulmonary thromboembolism: diagnosis with spiral volumetric CT with the single-breath-hold technique—comparison with pulmonary angiography. *Radiology*. 1992;185(2):381–387.
- Wiener RS, Schwartz LM, Woloshin S. Time trends in pulmonary embolism in the United States: Evidence of overdiagnosis. *Arch Intern Med*. 2011;171(9):831–837.
- Righini M, Robert-Ebadi H, Le Gal G. Diagnosis of pulmonary embolism: recent advances and trends. *Eur Respir J*. 2015;46(2):313–325.
- Stein PD, Matta F. Trends in case fatality rate in pulmonary embolism: analysis of the National Hospital Discharge Survey. *J Am Coll Cardiol*. 2012;60(19):1941–1946.
- Heit JA. Epidemiology of venous thromboembolism. *Nat Rev Cardiol*. 2015;12(8):464–474.
- Blokhiin IO, Lentz SR. Mechanisms of thrombosis in obesity. *Curr Opin Hematol*. 2013;20(5):437–444.
- Stein PD, Beemath A, Olson RE. Obesity as a risk factor in venous thromboembolism. *Am J Med*. 2005;118(9):978–980.
- Khorana AA. Cancer-associated thrombosis: updates and controversies. *Hematology Am Soc Hematol Educ Program*. 2012;2012:626–630.
- Anderson FA Jr, Spencer FA. Risk factors for venous thromboembolism. *Circulation*. 2003;107(23 Suppl 1):I9–I16.
- James AH. Venous thromboembolism in pregnancy. *Arterioscler Thromb Vasc Biol*. 2009;29(3):326–331.
- Lodigiani C, Iapichino G, Carenzo L, et al. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. *Thromb Res*. 2020;191:9–14.
- Litjens JF, Leclerc M, Chochois C, et al. High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients. *J Thromb Haemost*. 2020;18(7):1743–1746.
- Cohen AT, Agnelli G, Anderson FA, et al. Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. *Thromb Haemost*. 2007;98(4):756–764.
- Kearon C, Akl EA, Ornelas J, et al. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. *Chest*. 2016;149(2):315–352.
- Schulman S, Kearon C, Kakkar AK, et al. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. *N Engl J Med*. 2013;368(8):709–718.
- Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). *Lancet*. 1999;353(9162):1386–1389.
- Torbicki A, Perrier A, Konstantinides S, et al. Guidelines on the diagnosis and management of acute pulmonary embolism. *Eur Heart J*. 2008;29(18):2276–2315.
- Miniati M, Prediletto R, Formichi B, et al. Accuracy of clinical assessment in the diagnosis of pulmonary embolism. *Am J Respir Crit Care Med*. 1999;159(3):864–871.
- Couturaud F, Le Mao R, Tromeur C. Clinical presentation of pulmonary embolism. *Vasc Med*. 2010;15(5):307–314.
- Jaff MR, McMurtry MS, Archer SL, et al. Management of massive and submassive pulmonary embolism. *Circulation*. 2011;123(16):1788–1830.
- Kucher N, Goldhaber SZ. Management of massive pulmonary embolism. *Circulation*. 2005;112(2):e28–e32.
- Bagot CN, Arya R. Virchow and his triad: a question of attribution. *Br J Haematol*. 2008;143(2):180–190.
- Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). *Chest*. 2008;133(6 Suppl):381S–453S.
- Arya R, Barnes JA, Hossain U, et al. Long-haul flights and thromboembolism: a serious problem or just hype? *J Thromb Haemost*. 2006;4(3):763–764.
- Lee AY, Levine MN. Venous thromboembolism and cancer: risks and outcomes. *Circulation*. 2003;107(23 Suppl 1):I17–I21.
- Heit JA, Kobbervig CE, James AH, et al. Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. *Ann Intern Med*. 2005;143(10):697–706.
- Wu CQ, Grandi SM, Filion KB, et al. Risk of venous thromboembolism among users of contraceptive patches and vaginal rings: a systematic review and meta-analysis. *BMJ*. 2015;350:h2135.
- Piazza G, Campia U, Hurwitz S, et al. Registry of Arterial and Venous Thromboembolic Complications in Patients With COVID-19. *J Am Coll Cardiol*. 2020;76(18):2060–2072.
- Kujovich JL. Factor V Leiden thrombophilia. *Genet Med*. 2011;13(1):1–16.
- Prandoni P, Villalta S, Bagatella P, et al. The clinical course of deep-vein thrombosis. *Ann Intern Med*. 1996;125(1):1–7.
- Heit JA. The epidemiology of venous thromboembolism in the community: implications for prevention and management. *J Thromb Thrombolysis*. 2006;21(1):23–29.

39. Chan WS, Rey E, Kent NE, et al. Venous thromboembolism and antithrombotic therapy in pregnancy. *J Obstet Gynaecol Can.* 2014;36(6):527–553.
40. Amin AN, Stenkowski S, Lin J, Yang G. Thromboprophylaxis rates in US medical centers: success or failure? *J Thromb Haemost.* 2007;5(8):1610–1616.
41. Righini M, Van Es J, Den Exter PL, et al. Age-adjusted D-dimer cutoff levels to rule out pulmonary embolism: the ADJUST-PE study. *JAMA.* 2014;311(11):1117–1124.
42. Donato AA, Khoche S, Santora J, Wagner B. Clinical outcomes in patients with a low pretest probability of pulmonary embolism and negative D-dimer result: a meta-analysis. *JAMA.* 2008;299(8):919–928.
43. Wells PS, Anderson DR, Rodger M, et al. Derivation of a simple clinical model to categorize patients' probability of pulmonary embolism: increasing the models utility with the SimpliRED D-dimer. *Thromb Haemost.* 2000;83(3):416–420.
44. Wolf SJ, McCubbin TR, Feldhaus KM, Faragher JP, Adcock DM. Prospective validation of Wells Criteria in the evaluation of patients with suspected pulmonary embolism. *Ann Emerg Med.* 2004;44(5):503–510.
45. Le Gal G, Righini M, Roy PM, et al. Prediction of pulmonary embolism in the emergency department: the revised Geneva score. *Ann Intern Med.* 2006;144(3):165–171.
46. Schouten HJ, Geersing GJ, Koek HL, Zuithoff NP, Janssen KJ, Moons KG. Diagnostic accuracy of D-dimer testing in older patients with suspected venous thromboembolism: a systematic review. *JAMA.* 2013;310(22):2492–2500.
47. Kabrhel C, Camargo CA Jr, Goldhaber SZ. Clinical gestalt and the diagnosis of pulmonary embolism: does experience matter? *Chest.* 2005;127(5):1627–1630.
48. Penalzo A, Verschuren F, Meyer G, Quentin-Georget S, Soulie C, Thys F. Comparison of the Wells score with the revised Geneva score for assessing suspected pulmonary embolism: meta-analysis. *BMJ.* 2012;344:e383.
49. Lim W. Using D-dimer to diagnose pulmonary embolism. *BMJ.* 2014;349:g5072.
50. Stein PD, Fowler SE, Goodman LR, et al. Multidetector computed tomography for acute pulmonary embolism. *N Engl J Med.* 2006;354(22):2317–2327.
51. Schoepf UJ, Costello P. CT angiography for diagnosis of pulmonary embolism: state of the art. *Radiology.* 2004;230(2):329–337.
52. Parker JA, Coleman RE, Grady E, et al. SNM practice guideline for lung scintigraphy 4.0. *J Nucl Med Technol.* 2012;40(1):57–65.
53. Worsley DF, Alavi A, Aronchick JM, Chen JT, Greenspan RH, Ravin CE. Chest radiographic findings in patients with acute pulmonary embolism: observations from the PIOPED Study. *Radiology.* 1993;189(1):133–136.
54. Musset D, Parent F, Meyer G, et al. Diagnostic strategy for patients with suspected pulmonary embolism: a multicentre outcome study. *Lancet.* 2002;360(9349):1914–1920.
55. Kasper W, Konstantinides S, Geibel A, et al. Prognostic significance of right ventricular afterload stress detected by echocardiography in acute pulmonary embolism. *Circulation.* 1997;95(6):1356–1363.
56. Janata K, Holzer M, Kurtaran A, et al. Troponin I levels in patients with acute pulmonary embolism predict 30-day outcome. *Intensive Care Med.* 2003;29(6):1000–1005.
57. Lankeit M, Jiménez D, Kostrubiec M, et al. Predictive value of the high-sensitivity troponin T assay and the simplified PESI score for risk stratification of normotensive patients with acute PE. *Chest.* 2012;141(5):1264–1271.
58. Di Nisio M, Squizzato A, Rutjes AW, Büller HR, Zwinderman AH, Bossuyt PM. Diagnostic accuracy of D-dimer test for exclusion of venous thromboembolism: a systematic review. *J Thromb Haemost.* 2007;5(2):296–304.
59. Konstantinides SV, Meyer G, Becattini C, et al. 2019 ESC guidelines for the diagnosis and management of acute pulmonary embolism. *Eur Heart J.* 2020;41(4):543–603.
60. Kucher N, Rossi E, De Rosa M, Goldhaber SZ. Massive pulmonary embolism. *Circulation.* 2006;113(4):577–582.
61. Stein PD, Hull RD, Kayali F, et al. D-dimer for the exclusion of acute venous thrombosis and pulmonary embolism: a systematic review. *Ann Intern Med.* 2004;140(8):589–602.
62. Lee AY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. *N Engl J Med.* 2003;349(2):146–153.
63. Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. *N Engl J Med.* 2009;361(24):2342–2352.
64. Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of acute venous thromboembolism. *N Engl J Med.* 2013;369(9):799–808.
65. EINSTEIN-PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. *N Engl J Med.* 2012;366(14):1287–1297.
66. Hirsh J, Guyatt G, Albers GW, et al. Antithrombotic and thrombolytic therapy: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest.* 2008;133(6 Suppl):110S–112S.
67. Wan S, Quinlan DJ, Agnelli G, Eikelboom JW. Thrombolysis compared with heparin for the initial treatment of pulmonary embolism. *Circulation.* 2004;110(6):744–749.
68. Meyer G, Vicaute E, Danays T, et al. Fibrinolysis for patients with intermediate-risk pulmonary embolism. *N Engl J Med.* 2014;370(15):1402–1411.
69. Chatterjee S, Chakraborty A, Weinberg I, et al. Thrombolysis for pulmonary embolism and risk of all-cause mortality, major bleeding, and intracranial hemorrhage: a meta-analysis. *JAMA.* 2014;311(23):2414–2421.
70. Kuo WT, Banerjee A, Kim PS, et al. Pulmonary embolism response teams: multidisciplinary approach to pulmonary embolism treatment. *J Am Coll Cardiol Interv.* 2016;9(12):1234–1241.
71. Dohle DS, El Beyrouti H, Oezkur M, et al. Early surgical pulmonary embolectomy in patients with massive pulmonary embolism: a 10-year single-center experience. *J Thorac Cardiovasc Surg.* 2015;150(1):131–138.
72. Decousus H, Leizorovicz A, Parent F, et al. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. *N Engl J Med.* 1998;338(7):409–415.
73. Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. *Chest.* 2016;149(2):315–352.
74. Leung AN, Bull TM, Jaeschke R, et al. An official American Thoracic Society/Society of Thoracic Radiology clinical practice guideline: evaluation of suspected pulmonary embolism in pregnancy. *Radiology.* 2012;262(2):635–646.
75. Young AM, Marshall A, Thirlwall J, et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism. *N Engl J Med.* 2018;378(7):615–624.
76. Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest.* 2012;141(2 Suppl):e419S–e494S.
77. Laporte S, Mismetti P, Décousus H, et al. Clinical predictors for fatal pulmonary embolism in 15,520 patients with

- venous thromboembolism. *Arch Intern Med.* 2008;168(9):935–940.
78. Goldhaber SZ. Pulmonary embolism. *N Engl J Med.* 1998;339(2):93–104.
 79. Jiménez D, Aujesky D, Moores L, et al. Simplification of the pulmonary embolism severity index for prognostication in patients with acute symptomatic pulmonary embolism. *Arch Intern Med.* 2010;170(15):1383–1389.
 80. Aujesky D, Obrosky DS, Stone RA, et al. Derivation and validation of a prognostic model for pulmonary embolism. *Am J Respir Crit Care Med.* 2005;172(8):1041–1046.
 81. Heit JA, Silverstein MD, Mohr DN, et al. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. *Arch Intern Med.* 2000;160(6):761–768.
 82. Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. *Chest.* 2016;149(2):315–352.
 83. Klok FA, van Kralingen KW, van Dijk AP, et al. Quality of life in long-term survivors of acute pulmonary embolism. *Chest.* 2010;138(6):1432–1440.
 84. Pengo V, Lensing AW, Prins MH, et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. *N Engl J Med.* 2004;350(22):2257–2264.
 85. Pepke-Zaba J, Delcroix M, Lang I, et al. Chronic thromboembolic pulmonary hypertension (CTEPH): results from an international prospective registry. *Circulation.* 2011;124(18):1973–1981.
 86. Mayer E, Jenkins D, Lindner J, et al. Surgical management and outcome of patients with chronic thromboembolic pulmonary hypertension: results from an international prospective registry. *J Thorac Cardiovasc Surg.* 2011;141(3):702–710.
 87. Ghofrani HA, D'Armini AM, Grimminger F, et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. *N Engl J Med.* 2013;369(4):319–329.
 88. Klok FA, van der Hulle T, den Exter PL, et al. Benefits of a structured post-pulmonary embolism follow-up program. *J Thromb Haemost.* 2017;15(4):688–693.
 89. Deltas C, Tschape M, Seeber V, et al. Management of pulmonary embolism: follow-up and long-term outcomes. *Hamostaseologie.* 2020;40(3):289–295.